Subtopic Deep Dive

Melittin Anticancer Mechanisms
Research Guide

What is Melittin Anticancer Mechanisms?

Melittin anticancer mechanisms refer to the pore-forming, apoptosis-inducing, and chemotherapeutic-synergistic actions of the major bee venom peptide that selectively disrupt cancer cell membranes.

Melittin targets lipid bilayers in cancer cells, forming pores that lead to necrosis or apoptosis through mitochondrial pathways (Gajski and Garaj-Vrhovac, 2013, 294 citations). It suppresses growth factor receptors in HER2-enriched and triple-negative breast cancer (Duffy et al., 2020, 153 citations). Research spans over 20 papers from 2012-2021, with foundational work on NSCLC inhibition (Choi et al., 2014, 69 citations).

15
Curated Papers
3
Key Challenges

Why It Matters

Melittin addresses multidrug resistance by directly lysing cancer cell membranes, bypassing efflux pumps, as shown in conjugates for enhanced delivery (Rady et al., 2017, 362 citations). Lipid nanoparticles with melittin target lymph nodes to elicit systemic anti-tumor immunity (Yu et al., 2020, 228 citations). In breast cancer models, it inhibits HER2 and EGFR activation, reducing tumor growth (Duffy et al., 2020, 153 citations). These properties position melittin for clinical translation in oncology, improving outcomes in resistant cancers.

Key Research Challenges

Hemolytic Toxicity

Melittin's pore-forming action lacks selectivity between cancer and normal cells, causing hemolysis at therapeutic doses (Gajski and Garaj-Vrhovac, 2013, 294 citations). Conjugation strategies mitigate this but require optimization for bioavailability (Rady et al., 2017, 362 citations).

Delivery Optimization

Poor pharmacokinetics limit systemic use, necessitating nanoparticles or conjugates for lymph node targeting (Yu et al., 2020, 228 citations). Stability in vivo and tumor penetration remain barriers despite advances in lipid formulations.

Clinical Translation

Variability in bee venom composition hinders standardization, as noted in bioactive compound reviews (Cornara et al., 2017, 441 citations). Lack of large-scale RCTs delays progression from preclinical models to human trials (Lee et al., 2014, 80 citations).

Essential Papers

1.

Therapeutic Properties of Bioactive Compounds from Different Honeybee Products

Laura Cornara, Marco Biagi, Jianbo Xiao et al. · 2017 · Frontiers in Pharmacology · 441 citations

Honeybees produce honey, royal jelly, propolis, bee venom, bee pollen, and beeswax, which potentially benefit to humans due to the bioactives in them. Clinical standardization of these products is ...

2.

Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy

Islam Rady, Imtiaz A. Siddiqui, Mohamed I. Rady et al. · 2017 · Cancer Letters · 362 citations

3.

Melittin: A lytic peptide with anticancer properties

Goran Gajski, Vera Garaj‐Vrhovac · 2013 · Environmental Toxicology and Pharmacology · 294 citations

4.

From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery

Karla de Castro Figueiredo Bordon, Camila Takeno Cologna, Elisa Corrêa Fornari-Baldo et al. · 2020 · Frontiers in Pharmacology · 282 citations

Animal poisons and venoms are comprised of different classes of molecules displaying wide-ranging pharmacological activities. This review aims to provide an in-depth view of toxin-based compounds f...

5.

Antioxidant Activity in Bee Products: A Review

Marianna Martinello, Franco Mutinelli · 2021 · Antioxidants · 274 citations

Bee products have been used since ancient times both for their nutritional value and for a broad spectrum of therapeutic purposes. They are deemed to be a potential source of natural antioxidants t...

6.

Anti-Inflammatory Applications of Melittin, a Major Component of Bee Venom: Detailed Mechanism of Action and Adverse Effects

Gihyun Lee, Hyunsu Bae · 2016 · Molecules · 250 citations

Inflammation is a pervasive phenomenon triggered by the innate and adaptive immune systems to maintain homeostasis. The phenomenon normally leads to recovery from infection and healing, but when no...

7.

Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response

Xiang Yu, Yanfeng Dai, Yifan Zhao et al. · 2020 · Nature Communications · 228 citations

Abstract Targeted delivery of a nanovaccine loaded with a tumor antigen and adjuvant to the lymph nodes (LNs) is an attractive approach for improving cancer immunotherapy outcomes. However, the app...

Reading Guide

Foundational Papers

Start with Gajski and Garaj-Vrhovac (2013, 294 citations) for core lytic mechanisms, then Choi et al. (2014, 69 citations) for NSCLC death receptor pathways, and Zhang et al. (2014, 45 citations) for PTEN restoration in HepG2 cells.

Recent Advances

Study Duffy et al. (2020, 153 citations) for breast cancer receptor suppression, Yu et al. (2020, 228 citations) for lymph node targeting, and Carpena et al. (2020, 171 citations) for venom bioactives.

Core Methods

Core techniques: trypan blue viability (Choi 2014), lipid nanoparticle formulation (Yu 2020), Western blot for receptor/PTEN expression (Duffy 2020; Zhang 2014).

How PapersFlow Helps You Research Melittin Anticancer Mechanisms

Discover & Search

Research Agent uses searchPapers and exaSearch to query 'melittin pore formation cancer apoptosis', retrieving 250M+ OpenAlex papers including Rady et al. (2017, 362 citations). citationGraph maps connections from Gajski (2013, 294 citations) to recent works like Yu et al. (2020), while findSimilarPapers expands to bee venom synergies.

Analyze & Verify

Analysis Agent applies readPaperContent to extract mechanisms from Duffy et al. (2020), then verifyResponse with CoVe checks claims against Choi et al. (2014). runPythonAnalysis processes dose-response data from Gajski (2013) via pandas for IC50 curves; GRADE grading scores evidence quality for apoptosis pathways.

Synthesize & Write

Synthesis Agent detects gaps in melittin-chemotherapy synergies post-Rady (2017), flagging contradictions in toxicity data. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing 20+ papers, latexCompile for publication-ready PDFs, and exportMermaid for pore-formation diagrams.

Use Cases

"Extract dose-response data from melittin cancer papers and plot IC50 curves"

Research Agent → searchPapers → Analysis Agent → readPaperContent (Gajski 2013) → runPythonAnalysis (pandas/matplotlib IC50 plot) → matplotlib figure output with statistical fits.

"Write LaTeX review on melittin breast cancer mechanisms citing Duffy 2020"

Synthesis Agent → gap detection → Writing Agent → latexEditText (draft section) → latexSyncCitations (add Duffy, Yu refs) → latexCompile → PDF with inline citations and figures.

"Find GitHub code for melittin nanoparticle simulations"

Research Agent → paperExtractUrls (Yu 2020) → paperFindGithubRepo → githubRepoInspect → code snippets for lipid nanoparticle dynamics models.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers (50+ melittin papers) → citationGraph → GRADE grading → structured report on mechanisms. DeepScan applies 7-step analysis with CoVe checkpoints to verify apoptosis claims from Choi (2014). Theorizer generates hypotheses on melittin-HER2 synergies from Duffy (2020) literature synthesis.

Frequently Asked Questions

What defines melittin anticancer mechanisms?

Melittin anticancer mechanisms involve pore formation disrupting cancer membranes, apoptosis via mitochondrial pathways, and growth factor receptor inhibition (Gajski and Garaj-Vrhovac, 2013; Duffy et al., 2020).

What are key methods in melittin research?

Methods include cell viability assays (trypan blue, Gajski 2013), nanoparticle conjugation (Yu et al., 2020), and receptor activation studies (Duffy et al., 2020).

What are the highest-cited papers?

Top papers are Rady et al. (2017, 362 citations) on conjugates, Gajski and Garaj-Vrhovac (2013, 294 citations) on lytic properties, and Cornara et al. (2017, 441 citations) on bee products.

What open problems exist?

Challenges include reducing hemolytic toxicity, improving delivery (Rady 2017), and standardizing venom variability for clinical trials (Cornara 2017).

Research Healthcare and Venom Research with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Melittin Anticancer Mechanisms with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers